The risk for opportunistic infections in inflammatory bowel disease with biologics: an update

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet (London, England). 2017;389:1756–1770.
   PubMed Web of Science ®Google Scholar
• Torres J, Mehandru S, Colombel J-F, et al. Crohn’s disease. Lancet (London, England). 2017;389:1741–1755.
   PubMed Web of Science ®Google Scholar
• Soetikno R, Kaltenbach T, McQuaid KR, et al. Paradigm shift in the surveillance and management of dysplasia in inflammatory bowel disease (west). Dig Endosc. 2016;28:266–273.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Panaccione R, Bossuyt P, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet. 2017; 390:2779-2789.
   Google Scholar
• Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324–1338.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Narula N, Peyrin-Biroulet L. Management strategies to improve outcomes of patients with inflammatory bowel diseases. Gastroenterology. 2016;152:351–361.e5.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohn’s Colitis. 2014;8:443–468.
   Google Scholar
• WHO. Hepatitis C [Internet]. WHO. World Health Organization; 2017 [cited 2018 Feb 17]. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
   Google Scholar
• CCFA. Health maintenance checklist for adult IBD patients [Internet]. [cited 2018 Feb 17]. Available from: http://www.crohnscolitisfoundation.org/science-and-professionals/programs-materials/ccfa-health-maintenance.pdf.
   Google Scholar
• Cornerstones checklist for IBD patients [Internet]. [cited 2018 Feb 11]. Available from: http://www.crohnscolitisfoundation.org/science-and-professionals/programs-materials/ibd-nurses/best-practices/cornerstones-checklist.pdf.
   Google Scholar
• Basu PP, Shah NJ, Kavali L, et al. Sofosbuvir, ledipasvir in IBD treated patients with advanced biologics including ribavirin eradicating chronic hepatitis C: SOLATAIRE C Trial. A multi-center clinical prospective pilot study. Hpb. 2016;18:e299.
   Google Scholar
• von Felden J, Scheurich C, Yamamura J, et al. Successful treatment of chronic hepatitis C with ground ledipasvir/sofosbuvir in a patient with Crohn’s disease and short bowel syndrome. J Viral Hepat. 2018;25:214–215.
   PubMed Web of Science ®Google Scholar
• WHO. Hepatitis B [Internet]. WHO. World Health Organization; 2017 [cited 2018 Feb 18]. Available from: http://www.who.int/mediacentre/factsheets/fs204/en/.
   Google Scholar
• Badia E, Barrio J, Fernández-Salazar L, et al. P827 Prevalence of viral hepatitis in patients with IBD: a multi-centre and population-based study. J Crohn’s Colitis. 2018;12:S534–S534.
   Google Scholar
• He Y, Xu P, Chen Y, et al. Prevalence and influences of hepatitis B virus infection on inflammatory bowel disease: a retrospective study in southern China. Int J Clin Exp Med. 2015;8:8078–8085.
   PubMed Web of Science ®Google Scholar
• Belle A, Baumann C, Bigard M-A, et al. Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases. Eur J Gastroenterol Hepatol. 2015;27:877–881.
   PubMed Web of Science ®Google Scholar
• Jiang H, Wang S, Deng M, et al. Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: a systematic review and meta-analysis. Vaccine. 2017;35:2633–2641.
   PubMed Web of Science ®Google Scholar
• Cossio-Gil Y, Martínez-Gómez X, Campins-Martí M, et al. Immunogenicity of hepatitis B vaccine in patients with inflammatory bowel disease and the benefits of revaccination. J Gastroenterol Hepatol. 2015;30:92–98.
   PubMed Web of Science ®Google Scholar
• Côté-Daigneault J, Peerani F, Macmahon E, et al. Management and prevention of herpes zoster in the immunocompromised inflammatory bowel disease patient: a clinical quandary. Inflamm Bowel Dis. 2016;22:2538–2547.
   PubMed Web of Science ®Google Scholar
• Long MD, Martin C, Sandler RS, et al. Increased risk of herpes zoster among 108 604 patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2013;37:420–429.
   PubMed Web of Science ®Google Scholar
• Farraye FA, Melmed GY, Lichtenstein GR, et al. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241–258.
   PubMed Web of Science ®Google Scholar
• Khan N, Shah Y, Trivedi C, et al. Safety of herpes zoster vaccination among inflammatory bowel disease patients being treated with anti-TNF medications. Aliment Pharmacol Ther. 2017;46:668–672.
   PubMed Web of Science ®Google Scholar
• Lal H, Cunningham AL, Godeaux O, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096.
   PubMed Web of Science ®Google Scholar
• Levin MJ, DeBiasi RL, Bostik V, et al. Herpes zoster with skin lesions and meningitis caused by 2 different genotypes of the oka varicella-zoster virus vaccine. J Infect Dis. 2008;198:1444–1447.
   PubMed Web of Science ®Google Scholar
• Cottone M, Renna S. Incidence of HSV and HPV with azathioprine. Nat Rev Gastroenterol Hepatol. 2009;6:444–445.
   PubMed Web of Science ®Google Scholar
• Cornerstones Health. IBD checklist for monitoring and prevention [Internet]. [cited 2018 Feb 19]. Available from: http://www.cornerstoneshealth.org/wp-content/uploads/2017/06/Monitoring-and-Prevention-3.10.2017.pdf.
   Google Scholar
• Cranston RD, Regueiro M, Hashash J, et al. A pilot study of the prevalence of anal human papillomavirus and dysplasia in a cohort of patients with IBD. Dis Colon Rectum. 2017;60:1307–1313.
   PubMedGoogle Scholar
• Ruel J, Ko HM, Roda G, et al. Anal neoplasia in inflammatory bowel disease is associated with HPV and perianal disease. Clin Transl Gastroenterol. 2016;7:e148.
   PubMed Web of Science ®Google Scholar
• Allegretti JR, Barnes EL, Cameron A. Are patients with inflammatory bowel disease on chronic immunosuppressive therapy at increased risk of cervical high-grade dysplasia/cancer? A meta-analysis. Inflamm Bowel Dis. 2015;21:1089–1097.
   PubMed Web of Science ®Google Scholar
• Influenza (Flu) | seasonal Influenza (Flu) | CDC [Internet]. [cited 2018 Feb 23]. Available from: https://www.cdc.gov/flu/index.htm.
   Google Scholar
• Launay O, Abitbol V, Krivine A, et al. Immunogenicity and safety of influenza vaccine in inflammatory bowel disease patients treated or not with immunomodulators and/or biologics: a two-year prospective study. J Crohn’s Colitis. 2015;9:1096–1107.
   Google Scholar
• deBruyn J, Fonseca K, Ghosh S, et al. Immunogenicity of influenza vaccine for patients with inflammatory bowel disease on maintenance infliximab therapy. Inflamm Bowel Dis. 2016;22::638–647.
   PubMed Web of Science ®Google Scholar
• Shirai S, Hara M, Sakata Y, et al. Immunogenicity of quadrivalent influenza vaccine for patients with inflammatory bowel disease undergoing immunosuppressive therapy. Inflamm Bowel Dis. 2018;00:1–10.
   Google Scholar
• Matsumoto H, Ohfuji S, Watanabe K, et al. Booster influenza vaccination does not improve immune response in adult inflammatory bowel disease patients treated with immunosuppressives: a randomized controlled trial. J Gastroenterol. 2015;50:876–886.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016;14:1385–1397.e10.
   PubMed Web of Science ®Google Scholar
• McConachie SM, Wilhelm SM, Bhargava A, et al. Biologic-induced infections in inflammatory bowel disease: the TNF-α antagonists. Ann Pharmacother. 2018;52:571-579.
   Web of Science ®Google Scholar
• Uyanikoglu A, Ermis F, Akyuz F, et al. Infliximab in inflammatory bowel disease: attention to adverse events. Eur Rev Med Pharmacol Sci. 2014;18:2337–2342.
   PubMed Web of Science ®Google Scholar
• Kelsen JR, Grossman AB, Pauly-Hubbard H, et al. Infliximab therapy in pediatric patients 7 years of age and younger. J Pediatr Gastroenterol Nutr. 2014;59:758–762.
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sandborn WJ, Reinisch W, et al. Long-term safety of adalimumab in clinical trials in adult patients with Crohn’s disease or ulcerative colitis. Aliment Pharmacol Ther. 2018;47:219–228.
   PubMed Web of Science ®Google Scholar
• Baddley JW, Winthrop KL, Chen L, et al. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the safety assessment of biologic therapy (SABER) study. Ann Rheum Dis. 2014;73:1942–1948.
   PubMed Web of Science ®Google Scholar
• Singh S, Heien HC, Sangaralingham LR, et al. Comparative effectiveness and safety of anti–tumor necrosis factor agents in biologic-naive patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2016;14:1120–1129.e6.
   PubMed Web of Science ®Google Scholar
• Alsaleh A, Gaidos JKJ, Kang L, et al. Timing of last preoperative dose of infliximab does not increase postoperative complications in inflammatory bowel disease patients. Dig Dis Sci. 2016;61:2602–2607.
   PubMed Web of Science ®Google Scholar
• Fumery M, Seksik P, Auzolle C, et al. Postoperative complications after ileocecal resection in crohn’s disease: a prospective study from the REMIND group. Am J Gastroenterol. 2017;112:337–345.
   PubMed Web of Science ®Google Scholar
• Lewinsohn DM, Leonard MK, Lobue PA, et al. Official American thoracic society/infectious diseases society of America/Centers for disease control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017;64:111–115.
   PubMed Web of Science ®Google Scholar
• Abitbol Y, Laharie D, Cosnes J, et al. Negative screening does not rule out the risk of tuberculosis in patients with inflammatory bowel disease undergoing anti-TNF treatment: a descriptive study on the GETAID cohort. J Crohn’s Colitis. 2016;10:1179–1185.
   Google Scholar
• Abreu C, Afonso J, Camila Dias C, et al. Serial tuberculosis screening in inflammatory bowel disease patients receiving anti-TNFα therapy. J Crohn’s Colitis. 2017;11:1223–1229.
   Google Scholar
• Taxonera C, Ponferrada Á, Riestra S, et al. Serial tuberculin skin tests improves the detection of latent tuberculosis infection in patients with inflammatory bowel disease. J Crohns Colitis. 2018.
   PubMed Web of Science ®Google Scholar
• Gonczi L, Gecse KB, Vegh Z, et al. Long-term efficacy, safety, and immunogenicity of biosimilar infliximab after one year in a prospective nationwide cohort. Inflamm Bowel Dis. 2017;23:1908–1915.
   PubMed Web of Science ®Google Scholar
• Park SH, Kim Y-H, Lee JH, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev Gastroenterol Hepatol. 2015;9:35–44.
   PubMedGoogle Scholar
• Jahnsen J, Detlie TE, Vatn S, et al. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: a Norwegian observational study. Expert Rev Gastroenterol Hepatol. 2015;9:S45–S52.
   PubMedGoogle Scholar
• Kirchgesner J, Lemaitre M, Carrat F, et al. Risk of serious and opportunistic infections associated with treatment of inflammatory bowel diseases. Gastroenterology. 2018
   PubMed Web of Science ®Google Scholar
• Colombel J-F, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66:839–851.
   PubMed Web of Science ®Google Scholar
• Ko HH, Bressler B. Natalizumab: pharmacology, clinical efficacy and safety in the treatment of patients with Crohn’s disease. Expert Rev Gastroenterol Hepatol. 2007;1:29–39.
   PubMedGoogle Scholar
• Card T, Xu J, Liang H, et al. What is the risk of progressive multifocal leukoencephalopathy in patients with ulcerative colitis or crohn’s disease treated with vedolizumab?. Inflamm Bowel Dis. 2018;24:953–959.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Ron Y, Avni-Biron I, et al. Efficacy and safety of vedolizumab for induction of remission in inflammatory bowel disease—the israeli real-world experience. Inflamm Bowel Dis. 2017;23:404–408.
   PubMed Web of Science ®Google Scholar
• Amiot A, Serrero M, Peyrin-Biroulet L, et al. One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study. Aliment Pharmacol Ther. 2017;46:310–321.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jiang X, et al. The real-world effectiveness and safety of vedolizumab for moderate–severe crohn’s disease: results from the US VICTORY consortium. Am J Gastroenterol. 2016;111:1147–1155.
   PubMed Web of Science ®Google Scholar
• Baumgart DC, Bokemeyer B, Drabik A, et al. Vedolizumab induction therapy for inflammatory bowel disease in clinical practice - a nationwide consecutive German cohort study. Aliment Pharmacol Ther. 2016;43:1090–1102.
   PubMed Web of Science ®Google Scholar
• Lightner AL, Raffals LE, Mathis KL, et al. Postoperative outcomes in vedolizumab-treated patients undergoing abdominal operations for inflammatory bowel disease. J Crohn’s Colitis. 2017;11:185–190.
   Google Scholar
• Schils N, De Buck van Overstraeten A, Vermeire S, et al. P445 Perioperative use of vedolizumab seems not associated with short-term postoperative infectious complications in patients with Crohn’s disease undergoing right hemicolectomy with ileocolonic anastomosis. J Crohn’s Colitis. 2017;11:S304–S304.
   Google Scholar
• Yamada A, Komaki Y, Patel N, et al. Risk of postoperative complications among inflammatory bowel disease patients treated preoperatively with vedolizumab. Am J Gastroenterol. 2017;112:1423–1429.
   PubMed Web of Science ®Google Scholar
• Law CCY, Narula A, Lightner AL, et al. Systematic review and meta-analysis: preoperative vedolizumab treatment and postoperative complications in patients with inflammatory bowel disease. J Crohn’s Colitis. 2018;12:538–545.
   Google Scholar
• Lukin D, Weiss A, Aniwan S, et al. Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched analysis. J Crohn’s Colitis. 2018;12:S036.
   Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375:1946–1960.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao -L-L, et al. Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med. 2012;367:1519–1528.
   PubMed Web of Science ®Google Scholar
• MacDonald JK. Anti-IL-12/23p40 antibodies for induction of remission in Crohn’s disease (Review). Cochrane Database Syst Rev. 2016;11:CD007572.
   Google Scholar
• Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease—the McGill experience. J Crohn’s Colitis. 2014;8:1516–1522.
   Google Scholar
• Harris KA, Horst S, Gadani A, et al. Patients with refractory Crohnʼs disease successfully treated with Ustekinumab. Inflamm Bowel Dis. 2016;22:397–401.
   PubMed Web of Science ®Google Scholar
• Ma C, Fedorak RN, Kaplan GG, et al. Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn’s disease: real world experience from a multicentre cohort. Aliment Pharmacol Ther. 2017;45:1232–1243.
   PubMed Web of Science ®Google Scholar
• Khorrami S, Ginard D, Marín-Jiménez I, et al. Ustekinumab for the treatment of refractory Crohnʼs disease. Inflamm Bowel Dis. 2016;22:1662–1669.
   PubMed Web of Science ®Google Scholar
• Greenup A-J, Rosenfeld G, Bressler B. Ustekinumab use in Crohn’s disease: a Canadian tertiary care centre experience. Scand J Gastroenterol. 2017;52:1354–1359.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Long-term efficacy and safety of ustekinumab in 122 refractory Crohn’s disease patients: a multicentre experience. Aliment Pharmacol Ther. 2018;47:588-595.
   PubMed Web of Science ®Google Scholar
• Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in ustekinumab-treated patients undergoing abdominal operations for Crohn’s disease. J Crohn’s Colitis. 2017.
   Google Scholar
• Panés J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66:1049–1059.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ghosh S, Panes J, et al. A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2014;12:1485–1493.e2.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Su C, Sands BE, et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376:1723–1736.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Wouters AG, Choy EH, et al. The safety and immunogenicity of live zoster vaccination in patients with rheumatoid arthritis before starting tofacitinib: a randomized phase II trial. Arthritis Rheumatol. 2017;69:1969–1977.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77:302–309.
   PubMed Web of Science ®Google Scholar
• Winthrop KL, Melmed GY, Vermeire S, et al. Herpes zoster infection in patients with ulcerative colitis receiving tofacitinib. Inflamm Bowel Dis. 2018;00:1–8.
   Google Scholar
• Howden CW, Lichtenstein GR. Meeting report: AGA biosimilars roundtable. Gastroenterology. 2018;154:e1–e5.
   PubMed Web of Science ®Google Scholar
• Hirten RP, Iacucci M, Shah S, et al. Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders. Clin Gastroenterol Hepatol. 2018
   Web of Science ®Google Scholar